MYHEP ALL TABLET (SOFOSBUVIR 400MG/VELPATASVIR 100MG)

Description

MYHEP ALL TABLET (SOFOSBUVIR 400MG/VELPATASVIR 100MG) — Complete Clinical and Patient Information Guide

Product Overview

MYHEP ALL TABLET (SOFOSBUVIR 400MG/VELPATASVIR 100MG) contains Sofosbuvir 400mg + Velpatasvir 100mg fixed-dose combination tablet as its active pharmaceutical ingredient, belonging to the pan-genotypic direct-acting antiviral (DAA) combination — NS5B inhibitor + NS5A inhibitor for HCV. It is clinically indicated for chronic hepatitis C virus (HCV) infection — all genotypes 1–6 — 12-week treatment achieving >95% SVR12 (cure) in treatment-naive patients and most treatment-experienced patients. This guide is prepared in accordance with YMYL (Your Money Your Life) content standards, drawing on regulatory prescribing information, peer-reviewed pharmacological literature, and established clinical guidelines. Cancer and specialty medications require specialist initiation and monitoring — this information is educational and does not replace professional medical guidance.

Sofosbuvir/velpatasvir (Myhep All) is a fixed-dose combination direct-acting antiviral (DAA) regimen for chronic hepatitis C virus (HCV) infection — a YMYL condition of highest clinical significance. HCV affects approximately 58 million people globally and causes progressive liver fibrosis, cirrhosis, and hepatocellular carcinoma. Sofosbuvir/velpatasvir 400mg/100mg once daily for 12 weeks achieves sustained virological response (SVR12 — functional cure) in >95% of patients across all HCV genotypes (1–6) — a treatment outcome that was inconceivable before the DAA era (when interferon-based treatment achieved <50% response with severe toxicity).

Mechanism of Action

Sofosbuvir is a nucleotide analogue NS5B polymerase inhibitor for hepatitis C virus (HCV). After cellular uptake and phosphorylation to its active triphosphate form (sofosbuvir-TP), it competitively inhibits the HCV NS5B RNA-dependent RNA polymerase — the viral enzyme responsible for replicating the HCV RNA genome. Sofosbuvir-TP acts as a chain terminator: it is incorporated into the growing viral RNA strand but lacks the 3′-hydroxyl group required for the next nucleotide addition, halting RNA replication. Velpatasvir is a pan-genotypic NS5A inhibitor — it targets the HCV NS5A protein, a multifunctional viral protein essential for RNA replication, assembly, and host immune evasion. The combination of sofosbuvir (NS5B inhibitor) + velpatasvir (NS5A inhibitor) provides pan-genotypic activity against HCV genotypes 1–6 with complementary mechanisms — achieving sustained virological response (SVR12) rates of >95% in most HCV genotype combinations without the need for interferon.

Clinical Indications

MYHEP ALL TABLET (SOFOSBUVIR 400MG/VELPATASVIR 100MG) is indicated for chronic hepatitis C virus (HCV) infection — all genotypes 1–6 — 12-week treatment achieving >95% SVR12 (cure) in treatment-naive patients and most treatment-experienced patients. Specialist confirmation of diagnosis, eligibility for treatment, and initiation of therapy are mandatory — self-diagnosis and self-treatment of these conditions can be dangerous and may delay or undermine appropriate clinical management.

Dosage and Administration

One tablet once daily for 12 weeks (all HCV genotypes). Take with or without food. No ribavirin addition required for most patients. Simpler and more effective than previous interferon-based regimens. Myhep All is a Mylan/Viatris generic sofosbuvir/velpatasvir — the first pan-genotypic single-tablet DAA regimen available at accessible pricing.

Contraindications

Hypersensitivity to sofosbuvir or velpatasvir. Concurrent amiodarone (potentially fatal bradycardia — absolute contraindication; wash-out period required). Concurrent rifampicin, carbamazepine, phenytoin, St John’s Wort (dramatically reduce sofosbuvir/velpatasvir levels — treatment failure). Hepatitis B co-infection must be assessed and managed before HCV treatment (risk of HBV reactivation).

Drug Interactions

Amiodarone: ABSOLUTE CONTRAINDICATION — severe symptomatic bradycardia (mechanism unclear — multiple cases of fatal bradycardia reported). Antacids: separate by 4 hours. H2 blockers: separate by 12 hours or take simultaneously. PPIs: omeprazole ≤20mg simultaneously can be used. P-gp inducers (rifampicin, St John’s Wort): dramatically reduce levels — avoid. Rosuvastatin: velpatasvir increases rosuvastatin levels — limit dose.

Adverse Effects

Generally very well tolerated. Headache, fatigue, nausea (most common — mild and transient). Bradycardia with amiodarone (requires cardiac monitoring if amiodarone cannot be avoided). Reactivation of hepatitis B (if HBV co-infection present).

Special Population Considerations

HCV CURE RATES: Sofosbuvir/velpatasvir provides >95% SVR12 (sustained virological response at 12 weeks = functional cure) in HCV genotypes 1–6 without the need for genotyping before prescribing — making pan-genotypic DAA therapy accessible to all HCV patients. MONITORING: HCV RNA quantification at baseline, week 4 (on-treatment virological response), and 12 weeks post-treatment (SVR12 = cure). LFTs before and during treatment to monitor hepatic function. HBV SCREENING: Screen for HBV before HCV treatment — HBV reactivation during HCV treatment can cause severe or fatal hepatitis; manage HBV with antiviral therapy if required. AMIODARONE WARNING: This interaction is fatal — any patient on amiodarone must have the drug stopped and an adequate washout period before starting sofosbuvir/velpatasvir.

Storage

Store Myhep All per manufacturer guidelines. Most oral tablets at room temperature (15–25°C) away from heat, light, and moisture. Injectable medications require refrigeration or specific temperature control — follow pharmacy instructions. Keep out of reach of children and dispose of expired medications through authorised pharmaceutical take-back services.

Frequently Asked Questions

Q: How should I store this medication?
A: Store at room temperature (15–25°C), away from direct sunlight, heat, and moisture. Keep in original packaging out of reach of children. Injectable oncology medications require specialised storage — follow manufacturer and pharmacy guidance. Do not use beyond the printed expiry date.

Q: What should I do if I miss a dose?
A: For most medications: take as soon as you remember unless it is nearly time for the next dose. Never double-dose. For oncology medications, missed doses should be discussed with your oncologist before taking. Do not stop cancer medications without oncologist guidance.

Q: Can hepatitis C be truly cured with this medication?
A: Yes — achieving SVR12 (undetectable HCV RNA at 12 weeks after completing treatment) is considered a functional cure for hepatitis C. Patients with SVR12 have <1% chance of viral relapse, normalised liver function, halted fibrosis progression, reduced (though not eliminated) hepatocellular carcinoma risk, and dramatically improved long-term liver-related outcomes. Sofosbuvir/velpatasvir achieves SVR12 in >95% of treatment-naive patients across all genotypes — one of the highest cure rates of any infectious disease treatment.

Evidence Base, Regulatory Status, and Quality Standards

The active ingredient in Myhep All has been evaluated in clinical trials and regulatory submissions reviewed by competent health authorities. Oncology and specialty medications are subject to stringent regulatory scrutiny given their risk-benefit profiles in serious conditions. Major oncology guidelines from ESMO, ASCO, NCCN, and relevant national bodies inform prescribing decisions. All medications should be obtained through licensed, regulated pharmacies with valid prescriptions from registered specialists to ensure receipt of authentic, quality-assured products. GMP compliance ensures consistent product quality, identity, strength, and purity.

Cancer and Specialty Medicine Clinical Context

Cancer represents the second leading cause of death globally, accounting for approximately 10 million deaths annually. Modern oncology has been transformed by targeted therapy — drugs designed around specific molecular alterations in cancer cells (BCR-ABL in CML, HER2 in breast cancer, EGFR/ALK in NSCLC, VEGFR in solid tumours) achieving outcomes unimaginable with conventional chemotherapy. The era of precision oncology requires molecular profiling of each patient’s tumour before prescribing targeted agents — EGFR testing for erlotinib/gefitinib, HER2 testing for trastuzumab, ALK testing for ceritinib, and BCR-ABL for imatinib.

Conventional chemotherapy agents (paclitaxel, carboplatin, cyclophosphamide, fluorouracil, epirubicin, oxaliplatin, irinotecan, gemcitabine, dacarbazine, cytarabine, etoposide) remain essential backbones of cancer treatment — often combined with targeted agents in multi-drug regimens. Their cytotoxic mechanisms targeting rapidly dividing cells inevitably affect normal bone marrow, GI mucosa, and hair follicles — explaining myelosuppression, mucositis, and alopecia as class-wide adverse effects that require supportive care.

Haematological malignancies — leukaemias, lymphomas, multiple myeloma — represent a distinct oncological domain where molecular-targeted drugs have achieved remarkable results: imatinib transformed CML from a uniformly fatal disease to one with near-normal life expectancy; rituximab dramatically improved lymphoma outcomes; and the IMiD class (thalidomide, lenalidomide, pomalidomide) has progressively extended myeloma survival.

Parasitic Disease and Tropical Medicine Context

Parasitic infections cause enormous global morbidity — lymphatic filariasis affects 120 million people causing disfiguring lymphoedema; onchocerciasis blinds millions in sub-Saharan Africa; intestinal helminths impair growth and cognition in hundreds of millions of children; scabies infects approximately 200 million people globally; and Giardia/Cryptosporidium cause millions of diarrhoeal episodes annually. Ivermectin, albendazole, mebendazole, and DEC are WHO Essential Medicines — available for low cost and capable of eliminating these diseases when deployed through mass drug administration programmes.

Evidence Base and Quality Standards

The active ingredients in this product range have been evaluated in landmark clinical trials forming the evidence base for modern oncology, infectious disease, and specialty medicine: IPASS (gefitinib in EGFR-mutant NSCLC), ALEX (alectinib in ALK+ NSCLC), BOLERO-2 (everolimus+exemestane), ATAC (anastrozole), COU-AA-301/302 (abiraterone), AFFIRM/PREVAIL (enzalutamide), INPULSIS (nintedanib), ASTRAL-1 to 4 (sofosbuvir/velpatasvir), and many others. GMP-compliant manufacturing ensures consistent pharmaceutical quality. Patients must obtain oncology and specialty medications from licensed pharmacies with valid prescriptions from registered specialists.

Patient Safety, Monitoring, and Adherence

Oncology and specialty pharmacotherapy requires active patient engagement for optimal outcomes. Adherence to oral cancer drugs is critical — missed doses of TKIs like imatinib, erlotinib, and enzalutamide directly reduce drug exposure and potentially allow tumour progression or drug resistance development. Studies in CML show that patients with <80% imatinib adherence have significantly worse molecular response rates and higher transformation risk. The same principle applies to endocrine therapy for breast cancer — patients discontinuing anastrozole or tamoxifen early have substantially higher recurrence rates. Adherence support, side effect management, and patient education are as important as drug selection.

Monitoring requirements for specialty medications are stringent and non-negotiable. FBC monitoring during chemotherapy and methotrexate therapy prevents life-threatening myelosuppression complications. LFT monitoring during TKI and anthracycline therapy detects hepatotoxicity before it becomes severe. Cardiac monitoring during trastuzumab and anthracycline therapy prevents irreversible cardiomyopathy. Molecular monitoring (BCR-ABL PCR, HCV RNA, HBV DNA) determines treatment response and guides duration decisions.

All patients on oncology and specialty medications benefit from structured support: specialist oncology nurse coordination, patient support groups, pharmacist medication counselling, and regular specialist review. Complex medication regimens should be clearly written, explained verbally, and reviewed at each clinical encounter to identify any confusion, interactions, or emerging side effects requiring management.

Responsible Use and Safe Disposal

Oncology medications — particularly oral cytotoxic agents (cyclophosphamide, capecitabine, temozolomide, methotrexate) — are hazardous drugs requiring careful handling. Pregnant women and those planning pregnancy should not handle broken or crushed oral cytotoxic tablets. Unused or expired medications must be returned to a licensed pharmacy for safe hazardous pharmaceutical disposal — never disposed of in household waste or toilet.

Multi-Disciplinary Oncology Care

Modern cancer management requires multi-disciplinary team (MDT) decision-making — integrating oncologists, surgeons, radiologists, pathologists, specialist nurses, and pharmacists to develop individualised treatment plans. Pharmacological therapy (chemotherapy, targeted agents, endocrine therapy, immunotherapy) is one component of comprehensive cancer care alongside surgery (with curative intent for localised disease), radiotherapy (definitive, adjuvant, or palliative), and supportive/palliative care. Clinical trials offer access to novel therapies and the opportunity to advance cancer treatment knowledge — eligible patients should be offered trial participation where available.

Oncology pharmacy practice has become a specialised discipline — oncology pharmacists review complex multi-drug regimens for interactions and dosing errors, prepare hazardous IV chemotherapy safely, counsel patients on managing side effects of oral cancer drugs, and monitor for drug-induced toxicities. The safe use of oncology medications depends on this specialised expertise at every step from prescription to administration.

Palliative and supportive care integration is equally important — managing cancer symptoms (pain, nausea, fatigue, dyspnoea) and treatment side effects (chemotherapy-induced nausea, peripheral neuropathy, immunosuppression, mucositis) maintains quality of life throughout the cancer journey. Early palliative care integration (not just end-of-life care) improves patient outcomes and quality of life even in patients receiving active curative therapy.

Drug Supply and Authentic Procurement

For oncology and specialty medicines, procurement from authenticated, licensed sources is critically important. Counterfeit cancer medications are a documented global public health problem — they range from diluted products (containing less active ingredient than labelled, providing inadequate treatment) to products containing no active ingredient, to products with contaminated or substituted ingredients causing direct harm. Always obtain cancer medications from licensed, regulated pharmacies with valid prescriptions. Indian regulatory authority (CDSCO) oversight and manufacturer GMP compliance provide assurance of product quality for domestically produced cancer medicines.

Important Medical Disclaimer

This product information guide is provided for general educational purposes only, prepared in accordance with YMYL (Your Money Your Life) content standards. All information draws on regulatory prescribing information, peer-reviewed pharmacological and oncological literature, and established clinical guidelines. It does not replace professional medical advice, diagnosis, or treatment from a qualified oncologist, haematologist, physician, or specialist pharmacist. Cancer drug therapy decisions require individualised assessment by qualified oncology professionals with full knowledge of the patient’s diagnosis, staging, molecular profile, performance status, and concurrent medications. Self-diagnosis and self-treatment of cancer and serious medical conditions can be life-threatening. Always consult a qualified specialist before starting, changing, or stopping any cancer or specialty medication.